"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Descriptor ID |
D009103
|
| MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
| Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 1 | 3 |
| 2011 | 4 | 1 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 7 | 0 | 7 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 4 | 0 | 4 |
| 2020 | 3 | 0 | 3 |
| 2021 | 5 | 2 | 7 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
Looking Beyond Physical Disability: Cognitive Impairment in Persons With Multiple Sclerosis. Rehabil Nurs. 2022 Sep-Oct 01; 47(5):179-186.
-
Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Mult Scler Relat Disord. 2022 Jul; 63:103922.
-
Current and Future Biomarkers in Multiple Sclerosis. Int J Mol Sci. 2022 May 24; 23(11).
-
Incomplete reporting of patient-reported outcomes in multiple sclerosis: A meta-epidemiological study of randomized controlled trials. Mult Scler Relat Disord. 2022 Jul; 63:103819.
-
Outcome measures assisting treatment optimization in multiple sclerosis. J Neurol. 2022 Mar; 269(3):1282-1297.
-
Impact of adherence to disease-modifying therapies on employment among veterans with multiple sclerosis. Disabil Rehabil. 2022 08; 44(16):4415-4420.
-
Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination. Ann Neurol. 2021 06; 89(6):1234-1239.
-
Pertussis Toxin Inhibits Encephalitogenic T-Cell Infiltration and Promotes a B-Cell-Driven Disease during Th17-EAE. Int J Mol Sci. 2021 Mar 13; 22(6).
-
CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS. Neurol Neuroimmunol Neuroinflamm. 2021 05; 8(3).
-
Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manag Care Spec Pharm. 2021 May; 27(5):639-649.